Adam Gridley, Allay Therapeutics CEO
September 15, 2021 07:00 AM EDT
Financing

Pain play­er Al­lay makes good on launch promis­es, lock­ing down lat­est fundrais­ing round to ad­vance lead im­plant

Kyle Blankenship

Drug­mak­ers in the pain space have a dif­fi­cult road to ap­proval, even out­side of opi­oids, but a fresh-faced start­up that launched this sum­mer felt con­fi­dent …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times